Mode
Text Size
Log in / Sign up
Phase 1 Completed N=20 Treatment

A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer

Source: ClinicalTrials.gov NCT01833546 ↗
Enrolled (actual)
20
Serious AEs
10.0%
Results posted
Oct 2018
Primary outcomePrimary: Number of Participants Who Experienced Any Dose-Limiting Toxicity (DLT) During First Cycle - Day 1 to 28 — 0; 0; 1; 0 Participants

Summary

This is a Japanese Phase 1, open-label, and dose-escalating trial of TH-302 as monotherapy in subjects with solid tumors and in combination with gemcitabine in subjects with pancreatic cancer.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants Who Experienced Any Dose-Limiting Toxicity (DLT) During First Cycle - Day 1 to 28
0; 0; 1; 0
SECONDARY
Number of Participants With Treatment-Emergent Adverse Events (TEAE), Serious TEAEs, TEAEs Leading to Death
3; 3; 8; 6; 0; 0
SECONDARY
Time to Reach Maximum Plasma Concentration (Tmax) of Evofosfamide and Its Metabolite (Bromo-isophosphoramide Mustard [Br-IPM])
0.550; 0.250; 0.392; 0.550; 0.22; 0.533
SECONDARY
Time to Reach Maximum Plasma Concentration (Tmax) of Gemcitabine and Its Metabolite (2',2'-Difluorodeoxyuridine [dFdU])
0.500; 0.500; 0.500; 0.500
SECONDARY
Maximum Observed Plasma Concentration (Cmax) of Evofosfamide and Its Metabolite (Bromo-isophosphoramide Mustard [Br-IPM])
6502.3; 10009.8; 14016.7; 9303.4; 7159.9; 10248.2
SECONDARY
Maximum Observed Plasma Concentration (Cmax) of Gemcitabine and Its Metabolite (2',2'-Difluorodeoxyuridine [dFdU])
22596.2; 21355.5; 33923.9; 33631.4
SECONDARY
Terminal Rate Constant Associated With the Terminal Elimination Phase (λz) of Evofosfamide and Its Metabolite (Bromo-isophosphoramide Mustard [Br-IPM])
1.012; 1.100; 1.094; 1.146; 1.007; 1.032
SECONDARY
Terminal Rate Constant Associated With the Terminal Elimination Phase (λz) of Gemcitabine and Its Metabolite (2',2'-Difluorodeoxyuridine [dFdU])
3.241; 3.171; 0.0895; 0.0870
SECONDARY
Apparent Terminal Half-life (t1/2) of Evofosfamide and Its Metabolite (Bromo-isophosphoramide Mustard [Br-IPM])
0.6850; 0.6304; 0.6334; 0.6049; 0.6881; 0.6716
SECONDARY
Apparent Terminal Half-life (t1/2) of of Gemcitabine and Its Metabolite (2',2'-Difluorodeoxyuridine [dFdU])
0.2139; 0.2186; 7.741; 7.964
SECONDARY
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Sampling Time With Concentration at or Above the Lower Limit of Quantitation (AUC[0-t]) of Evofosfamide and Its Metabolite (Bromo-isophosphoramide Mustard [Br-IPM])
5266.9; 7864.2; 10416.1; 5989.5; 5232.4; 8191.1
SECONDARY
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Sampling Time With Concentration at or Above the Lower Limit of Quantitation (AUC[0-t]) of Gemcitabine and Its Metabolite (2',2'-Difluorodeoxyuridine [dFdU])
10001.2; 9576.0; 139397.1; 116487.7
SECONDARY
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC [0-infinity]) of Evofosfamide and Its Metabolite (Bromo-isophosphoramide Mustard [Br-IPM])
5296.2; 7904.7; 10459.6; 6049.5; 5261.3; 8233.3
SECONDARY
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC [0-infinity]) of Gemcitabine and Its Metabolite (2',2'-Difluorodeoxyuridine [dFdU])
10719.5; 9996.0; 159014.1; 133203.0
SECONDARY
Apparent Total Body Clearance of (CL) of Evofosfamide
45.83; 43.05; 46.07; 56.23; 45.74; 41.74
SECONDARY
Apparent Total Body Clearance of (CL) of Gemcitabine
93.29; 101.04
SECONDARY
Apparent Volume of Distribution at Steady State (Vss) of Evofosfamide
21.71; 21.54; 21.79; 39.03; 20.26; 18.83
SECONDARY
Apparent Volume of Distribution at Steady State (Vss) of Gemcitabine
34.41; 43.71
SECONDARY
Apparent Volume of Distribution During Terminal Phase (Vz) of Evofosfamide
44.85; 39.16; 42.10; 49.07; 45.41; 40.44
SECONDARY
Apparent Volume of Distribution During Terminal Phase (Vz) of Gemcitabine
28.78; 30.14
SECONDARY
Cumulative Amount of Evofosfamide Excreted From Time Zero to Time After Dosing (Ae0-t)
22.913; 17.135; 38.771; 22.691; 11.674; 22.605
SECONDARY
Renal Clearance (CL) for Evofosfamide
4.35; 2.18; 3.72; 3.79; 2.23; 2.76
SECONDARY
Best Overall Response (BOR)
0; 0; 0; 0; 0; 0
SECONDARY
Number of Participants With Objective Response
0; 0; 0; 0
SECONDARY
Number of Participants With Disease Control
0; 0; 2; 2
SECONDARY
Number of Participants With Clinical Significant Laboratory Abnormalities and Vital Signs Abnormalities Reported as Treatment Emergent Adverse Events
3; 3; 8; 6; 0; 0
SECONDARY
Number of Participants With Abnormal Electrocardiogram (ECG) Findings Reported as Treatment Emergent Adverse Events (TEAEs)
0; 0; 3; 1
SECONDARY
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 2 or Higher Than 2
0; 0; 1; 0

Eligibility Criteria

Inclusion Criteria

  • At least 20 years of age
  • Signed written informed consent form
  • Histologically or cytologically confirmed advanced or metastatic solid tumor previously treated with one or more standard treatment regimen(s) or for which no effective therapy is available
  • Histologically or cytologically confirmed locally advanced unresectable or metastatic pancreatic adenocarcinoma previously untreated with chemotherapy or systemic therapy
  • Recovered from toxicities of prior anti-cancer treatment to Grade 1 or less
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Life expectancy of at least 3 months
  • Acceptable liver function, renal function, hematologic status and coagulation status as defined in the protocol
  • No clinically significant abnormalities in urinalysis
  • Effective contraception for both male and female subjects if the risk of conception exists
  • Other inclusion criteria apply

Exclusion Criteria

  • Prior anti-cancer treatment with more than 3 myelosuppressive cytotoxic chemotherapy regimens
  • Prior treatment with gemcitabine for their advanced or metastatic pancreatic cancer, except for radiosensitizing doses of gemcitabine
  • Prior radiotherapy to more than 30 percent of the bone marrow within 6 months prior to the trial entry
  • Cardiac disease with New York Heart Association (NYHA) Class 3 or 4, within 6 months prior to the trial entry
  • Clinically significant (that is, active) cardiovascular disease
  • Seizure disorders requiring anticonvulsant therapy
  • Known brain, leptomeningeal or epidural metastases (unless previously treated and well controlled for at least 3 months at the trial entry)
  • Previously treated malignancies other than the current disease for at least 5 years at the trial entry
  • Severe chronic obstructive or other pulmonary disease major surgery, within 4 weeks prior to the trial entry, without complete recovery
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
  • Anti-cancer treatment prior to trial entry
  • Participation in an investigational drug or device trial within 4 weeks prior to the trial entry
  • Known infection with human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C
  • A history of allergic reactions
  • Taking a medication that is either moderate or strong inhibitor or inducer of cytochrome P450 (CYP)3A4 or is a sensitive substrate of other cytochrome P450
  • Pregnancy or lactation period
  • Concomitant disease or condition that could interfere with the conduct of the trial, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this trial
  • Unwillingness or inability to comply with the trial protocol for any reason
  • Legal incapacity or limited legal capacity
  • Other exclusion criteria apply
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01833546). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search